A Phase II Neo-Adjuvant Study of Letrozole in Combination with Lapatinib in Post-Menopausal Patients with HER2-positive and Hormone Receptor-positive Operable Breast Cancer (SPORE).

Trial Profile

A Phase II Neo-Adjuvant Study of Letrozole in Combination with Lapatinib in Post-Menopausal Patients with HER2-positive and Hormone Receptor-positive Operable Breast Cancer (SPORE).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2012

At a glance

  • Drugs Lapatinib; Letrozole
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2010 Actual end date (1 Dec 2010) added as reported by ClinicalTrials.gov.
    • 01 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Planned End Date changed from 1 Jul 2010 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top